Background: Recent miRNA profiling studies have implicated the potential use of miRNAs as as diagnostic and prognostic indicators in acute myeloid leukemia (AML), which has been reportedly implicated in the interplay with certain mRNAs. Herein this study, we intend to characterize the functional relevance of SPOP/miR-183/METAP2 axis in AML in vivo and in vitro.
to U6) or mRNA (normalized to GAPDH) levels were determined by qRT-PCR using 2 − △△CT method. Table 1 Primer sequences for qRT-PCR.
mRNA/miR
Sequence ( (APOAF, Sigma-Aldrich, USA). Cells were treated differently and cultured for 48 h. The collected cells were incubated with 10 µL Annexin V-FITC and 5 µL PI for 15 min at room temperature without light exposure. A flow cytometer (Becton Dickinson, USA) was employed to examine the cell apoptosis and calculate the apoptosis rate.
Cell apoptosis assay by TUNEL staining in tissues An apoptosis detection kit (C1098, Beyotime, Shanghai, China) was employed for TUNEL assay in tissues. The sections were subjected to DNase-free proteinase K treatment at 37 °C for 15 min. Then, sections were stained in TUNEL solution at 37 °C for 60 min without light exposure. After being mounted with DAPI medium, sections were observed under a microscope to count the apoptosis rate.
Luciferase activity assay
The miR-183 promoter sequence (miR-183 WT) and mutation sequence (miR-183 Mut) that bind to β-catenin were synthesized. METAP2 mRNA 3'UTR sequence (METAP2 WT) and mutation sequence (METAP2 Mut) that bind to miR-183 were introduced into pGL3-basic vector (E1751, Promega, USA). The target fragment was inserted into pGL3 vector using T4 DNA ligase (M0204S, New England Biolabs, USA) after restriction digestion. Renilla luciferase plasmid and the constructed luciferase reporter plasmid were co-transfected with oe-NC, oe-β-catenin or mimics-NC, miR-183 mimics into HEK293T cells for 48 h transfection. The Dual-Luciferase® Repeat Assay System Kit (E1910, Promega, USA) was employed for assessing luciferase activity on the GloMax® 20/20 Luminometer (E5311, Promega, US). Relative luciferase activity = firefly luciferase activity/Renilla luciferase activity. All vectors were constructed by Sangon Biotech Co., Ltd., Shanghai, China.
ChIP assay
ChIP assays were performed using the EZ-Magna ChIP kit (EMD Millipore, USA). K562 and KG-1 cells were fixed with 1% paraformaldehyde and incubated with glycine for 10 min to produce DNA-protein cross-links. Cells were then lysed using cell lysis buffer and nuclear lysis buffer, and sonicated to produce 200-300 bp chromatin fragments. Next, the lysate was immunoprecipitated with magnetic protein A beads binding to the antibody. The rabbit IgG (ab172730, 1: 100, Abcam, UK) was added to the negative control, and βcatenin antibody (ab227499, 1: 1000, Abcam, UK) was added to the Anti-β-catenin group.
Finally, miR-183 promoter fragment in the precipitate was evaluated by qRT-PCR. miR-183
CHIP primer (F: 5'-GTCCTCTGGGGAGATAGACC-3', R: 5'-ACACTGCTTAATGCTCCACCC-3').
Immunofluorescence staining
The cells were fixed with 4% paraformaldehyde, and blocked with 5% goat serum (diluted with 0.3% PBST) for 1 h at room temperature. Cells were incubated with primary antibody rabbit anti-human β-catenin (ab227499, 
Results

SPOP overexpression accelerates AML cell proliferation and inhibits apoptosis
Analysis of GEPIA database revealed that SPOP was up-regulated in AML (p < 0.05, Fig. 1A ). Furthermore, the expression of SPOP in the peripheral blood of AML group was higher than that in the normal group (p < 0.05, Fig. 1B , C). Therefore, we speculate that SPOP may mediate cell activities in AML. To verify this hypothesis, we first examined the expressions of SPOP in four AML cell lines (HL60, K562, U937, and KG-1). The expression of SPOP in K562, U937, and KG-1 cells was higher than that in PBMC cells (p < 0.05, Fig. 1D , E). We selected K562 and KG-1 cells for subsequent experiments. The efficiency of overexpressing or silencing SPOP in K562 and KG-1 cells was validated. The results manifested that the expression of SPOP in the oe-SPOP group was higher than that in the oe-NC group, and that in the sh-SPOP-1 and sh-SPOP-2 groups was lower than that of the sh-NC group (p < 0.05, Fig. 1F , G). The sh-SPOP-1 group (sh-SPOP group) was selected for subsequent experiments, due to its stronger silencing efficiency than the sh-SPOP-2 group.
CCK-8 assay identified increased cell viability in response to oe-SPOP treatment, and lowered cell viability to sh-SPOP treatment ( Fig. 1H ). EdU assay manifested that EdUpositive cells was increased in response to oe-SPOP treatment, along with lowered cell proliferation in response to sh-SPOP treatment ( Fig. 1I ). Flow cytometric data revealed attenuated AML cell apoptosis in response to oe-SPOP treatment, and that in response to sh-SPOP treatment was facilitated ( Fig. 1J ). Together, SPOP overexpression accelerates the proliferation of AML cells and inhibits their apoptosis.
SPOP enhances β-catenin protein expression and nuclear translocation leading to elevated miR-183 expression
Prior evidence proposed that β-catenin can facilitate the occurrence of AML, and SPOP can indirectly enhance the stability and nuclear translocation of β-catenin in the cytoplasm in renal cancer cells [21, 22] . Therefore, we speculate that in AML cells, SPOP may also stabilize β-catenin expression and nuclear translocation in the cytoplasm. To verify this hypothesis, we first tested β-catenin expression in K562 and KG-1 cells. The treatment of oe-SPOP resulted in elevated total β-catenin protein level, and cytoplasmic and nuclear levels, while β-catenin protein level was diminished in the presence of sh-SPOP transduction ( Fig. 2A ). Immunofluorescence assay found increased β-catenin distribution in the nucleus and cytoplasm following treatment of oe-SPOP ( Fig. 2B ). Thus, in AML cells, SPOP can augment the stability of cytoplasm and nuclear translocation of β-catenin.
MiR-183 has been reportedly suggested to highly express in AML and stimulate the occurrence of this disease [18] . Besides, β-catenin and TCF bind to the miR-183 promoter region to enhance the miR-183 expression in liver cancer cells [23] ). Therefore, we speculate that the high expression of miR-183 in AML cells may also be regulated by βcatenin. First, we found that the expression of miR-183 in peripheral blood of the AML group was higher than that in the normal group (p < 0.05, Fig. 2C ). Next, we assessed the efficiency of overexpressing and silencing β-catenin. The expression of β-catenin was increased upon treatment of oe-β-catenin, and reduced upon treatment of sh-β-catenin-1 and sh-β-catenin-2 ( Fig. 2D , E). The sh-β-catenin-1 (sh-β-catenin group) with stronger silencing efficiency than sh-β-catenin-2 was selected for subsequent experiments. oe-βcatenin was co-transfected into HEK293T cells with miR-183 Wt and miR-183 Mut, respectively. Western blot assay revealed in the presence of miR-183 Wt and miR-183
Mut, the β-catenin expression was enhanced upon oe-β-catenin transduction versus oe-NC treatment (p < 0.05). The dual luciferase report assay suggested that the luciferase activity in the miR-183 Wt group increased following addition of oe-β-catenin, while the luciferase activity in the miR-183 Mut group did not change (Fig. 2F ). The CHIP assay manifested that relative to IgG, β-catenin enrichment in the miR-183 promoter region was elevated, and the enrichment was facilitated after overexpressing β-catenin ( Fig. 2G ). In addition, we unraveled that miR-183 expression was elevated by oe-SPOP and oe-βcatenin, and reduced by sh-SPOP and sh-β-catenin. Whereas, combined treatment of oe-SPOP + sh-β-catenin showed lower miR-183 expression than oe-β-catenin treatment, and combined treatment of sh-SPOP + oe-β-catenin showed higher miR-183 expression than sh-SPOP treatment (Fig. 2H ). These results indicate that SPOP accelerates β-catenin protein expression and nuclear translocation, thus elevating miR-183 expression.
MiR-183 overexpression enhances proliferation and inhibits apoptosis of AML cells by targeting METAP2
In order to further clarify the downstream mechanism of miR-183, we, through bioinformatic analysis, we obtained 8890 up-regulated and 7791 down-regulated mRNAs (Fig. 3A) , and intersected the mRNAs from different databases ( Fig. 3B ). In these four databases, 12 genes (GCLM, GNG12, METAP2, EXO1, TET1, RHOBTB1, YOD1, SMCO4, XPOT, GTF2H1, SPATS2, LRP6) were found in the intersection. No previous studies could be found on target relationship between miR-183 and METAP2. The GEPIA database analysis showed that METAP2 was down-regulated in AML samples (p < 0.05, Fig. 3C ). Moreover, our experimental data manifested that the expression of METAP2 in the AML group was lower than that in the Normal group (p < 0.05, Fig. 3D , E). The binding sites between miR-183 and METAP2 were predicted by Starbase database (Fig. 3F ).
In KG-1 and K562 cells, miR-183 mimics treatment resulted in increased miR-183 expression, and miR-183 inhibitor treatment resulted in diminished miR-183 expression ( Fig. 3G ). In the presence of METAP2 WT and METAP2 Mut, the expression of miR-183 was elevated in response to miR-183 mimics (p < 0.05). The dual luciferase report assay manifested that the luciferase activity in the METAP2 WT group was reduced upon miR-183 mimics treatment, and the luciferase activity didn't differ appreciably in the METAP2 Mut group (Fig. 3H ). Moreover, we found that, in KG-1 and K562 cells, the expression of METAP2 was lowered following miR-183 mimics treatment, and which was elevated in response to miR-183 inhibitor treatment ( Fig. 3I , J). The above data indicate that miR-183 targets and inhibits METAP2 expression.
Next, we further investigated whether miR-183 can expedite the proliferation and halt Together, SPOP affects the occurrence and growth of AML by mediating the expression of β-catenin and regulating the activation of miR-183/METAP2 axis.
Discussion
Current therapies, such as chemotherapy and allogeneic stem cell transplantation, for AML are commonly effective a limited population of younger and fit patients, but the majority of elder individuals suffer from unfavorable prognosis and low survival [1, 24] . Welldocumented evidence exists proving that multiple miRNAs have a critical role to play in orchestrating leukemia cell proliferation and apoptosis, which may potentially be used as therapeutic biomarkers [25, 26] . In this current study, the objective was to illuminate the molecular mechanism by which the SPOP-mediated miR-183/METAP2 axis fine-tunes the malignant phenotypes of AML cells (Fig. 7) .
The experimental data unveiled that SPOP and miR-183 were highly expressed, while However, in this study, we unmasked mechanistically that the oncogenic role of SPOP was realized through enhancing β-catenin protein expression and nuclear translocation, which elevated miR-183 expression. The enhancement that SPOP triggered in β-catenin protein expression as well as its nuclear translocation has been demonstrated previously in renal cancer [22] . Moreover, the oncogenic function of miR-183 in hepatocellular carcinoma was reported to be triggered by β-catenin activation, and silencing of CTNNB1 (β-catenin) could diminish expression of miR-183 [23] . In addition, the Wnt/β-catenin signaling activation has been highlighted to be implicated in the pathogenesis of AML due to its stimulation on cell cycle progression and suppression on apoptosis of AML cells [31].
Inhibition of β-catenin leads to concordantly restricted tumorigenic potential in AML [32] .
It is clear that SPOP-substrate protein interaction associates with the oncogenic SPOPsignaling pathways [28] . These evidences verify the pivotal function of miR-183 in the oncogenic SPOP role in AML.
Next, we further extended our understanding mechanistically by revealing that miR-183 specifically targeted and inversely regulated METAP2 expression. MiR-183 overexpression enhanced proliferation and repressed apoptosis of AML cells by targeting METAP2. METAP2
has been shown to exert anti-angiogenic activity and to conduct actions toward tumor suppression [15] . Further, the study of Frottin et al. documented that METAP2 could stimulate cell selectivity for a potent anti-cancer agent in synergy [33] . Moreover, we also carried a wide array of assays to validate that miR-183 inhibition and METAP2 overexpression could repress SPOP-induced proliferation and augment SPOP-inhibited apoptosis of AML cells. The in vivo experiments consistently validated that SPOP facilitated AML initiation by mediating β-catenin expression and the miR-183/METAP2 axis.
Conclusion
Thus, we strongly feel based on the evidence of this study that therapeutic strategies should be directed towards the down-regulation of SPOP and miR-183, which may potentially be a clinically viable targets in the treatment of AML. The oncogenic SPOP accelerated tumorigenesis and development of AML through miR-183-mediated METAP2
inhibition. As we further elucidate the epigenetic regulatory mechanisms underlying AML, there is great potential for translational applications for patients. Data comparison between two groups was performed using unpaired t test, and that among multiple groups using one-way ANOVA with Tukey's post hoc test. The experiment was repeated three times. Data comparison between two groups was performed using unpaired t test, and that among multiple groups using one-way ANOVA with Tukey's post hoc test. The experiment was repeated three times. 
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